Factors Affecting the Price of Caprelsa

Caprelsa (vandetanib), a multikinase inhibitor, has a price shaped by key factors. High R&D costs, from developing its activity against RET, VEGFR, and EGFR to clinical trials for medullary thyroid cancer, drive up pricing. 

Factors Affecting the Price of Caprelsa

 Patent exclusivity allows AstraZeneca to maintain market control, setting premium rates. Production complexities, including precise manufacturing of its formulations, add to costs. Market demand for targeted therapies in rare cancers and regional healthcare policies—such as insurance coverage and regulatory pricing rules—further influence the final price patients incur.